HHS Won't Invoke IP Rights To Lessen Xtandi Prices

By Dani Kass (February 8, 2024, 9:18 PM EST) -- The U.S. Department of Health and Human Services said it's unnecessary for the government to assert patent rights to Pfizer and Astellas' blockbuster cancer drug, Xtandi, in the hopes of lowering prices, determining that the drug is already widely available and that exercising those rights is unlikely to be effective....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.

A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!